Breath biomarkers could lead to non-invasive detection and monitoring for liver disease, diabetes, kidney disease, heart failure and other cardiometabolic diseases.
)

Cardiovascular & Metabolic Diseases

Breath biomarkers could lead to non-invasive detection and monitoring for liver disease, diabetes, kidney disease, heart failure and other cardiovascular and metabolic diseases

Find out more
Presentation
)

Webinar: Developing EVOC Probes for liver disease

As part of BBCon21, Giuseppe Ferrandino presents our work developing exogenous VOC probes for high sensitivity, high contrast detection of liver disease using breath

View Presentation
Non-invasive breath testing offers an attractive alternative to currently available diabetes tests for diagnosis and ongoing monitoring
)

Article: Insights into potential VOC biomarkers of diabetes

Non-invasive breath testing offers an attractive alternative to currently available diabetes tests for diagnosis and ongoing monitoring

Read Review
A non-invasive breath test could allow for cheaper screening and earlier intervention, when damage is less severe
)

Article: Examining candidate breath biomarkers for kidney disease

A non-invasive breath test could allow for cheaper screening and earlier intervention, when damage is less severe

View Publication
Current biomarkers of cardiovascular disease and heart function are accessed invasively and burdensome for the patient. Breath biomarkers could be of huge value.
)

Case Study: Could acetone be a biomarker of heart failure?

Current biomarkers of heart function are very invasive but evidence suggests breath acetone could be useful for both diagnosis and prognosis

Read Case study

We’ve worked on cardiovascular and metabolic disease with these groups:

University of Birmingham logo Cancer Research UK Logo Cleveland Clinic News

Recommended reading:

 

Cardiometabolic disease summary

Get in touch with Owlstone

Get in touch with our team to discuss how we can work together

Let's get started